Tumor genotype plays an important role in personalized treatment for lung cancer patients, where mutations in common proto-oncogenes and oncogenes such as EGFR, ALK, ROS1, and RET have been associated with radiomic signatures see 11 for review. This evidence concerns the gene EGFR and lung cancer.